Submit IND application for ADX-248
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Jan 2024
- Due
- 31 Dec 2024
- Checked
- 6 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“an IND application of next-generation investigational RASP modulator ADX-248 is expected to be submitted in 2024.”
What we found
Evidence strength A What the grades mean
Company announced IND submission expected in 2024, but in October 2025 pushed expected timing to 2026.
-
A Aldeyra Therapeutics Provides Clinical and Regulatory Update
“IND application of ADX-248 expected to be submitted to FDA for Phase 1/2 clinical trial in dry age-related macular degeneration patients with dark adaptation deficit in 2024.” ✓ confirmed on the page
-
B Aldeyra Therapeutics Press Release dated October 28, 2025
“anticipated timing for the filing of an Investigational New Drug (IND) application was updated to 2026.”
Checked 6 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory filing
- Indicative materiality
- Medium rules
- Action
- Submit
- Deliverable
- ADX-248 IND application
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-ALDX-003538 · Corrections policy